30
Participants
Start Date
January 30, 2024
Primary Completion Date
November 1, 2026
Study Completion Date
December 31, 2028
CPI-0209
A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
carboplatin
Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
RECRUITING
Magee-Womens Research Institute / UPMC Magee Womens Hospital, Pittsburgh
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
National Cancer Institute (NCI)
NIH
Lan Coffman
OTHER